HRP20200491T1 - Novi kompleks koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za liječenje kolorektalnog karcinoma - Google Patents

Novi kompleks koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za liječenje kolorektalnog karcinoma Download PDF

Info

Publication number
HRP20200491T1
HRP20200491T1 HRP20200491TT HRP20200491T HRP20200491T1 HR P20200491 T1 HRP20200491 T1 HR P20200491T1 HR P20200491T T HRP20200491T T HR P20200491TT HR P20200491 T HRP20200491 T HR P20200491T HR P20200491 T1 HRP20200491 T1 HR P20200491T1
Authority
HR
Croatia
Prior art keywords
complex
epitopes
peptide
cell
colorectal cancer
Prior art date
Application number
HRP20200491TT
Other languages
English (en)
Croatian (hr)
Inventor
Madiha DEROUAZI
Elodie BELNOUE
Original Assignee
Amal Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amal Therapeutics Sa filed Critical Amal Therapeutics Sa
Publication of HRP20200491T1 publication Critical patent/HRP20200491T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4277—Fusion proteins originating from gene translocation in cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16233—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20200491TT 2015-03-16 2016-03-16 Novi kompleks koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za liječenje kolorektalnog karcinoma HRP20200491T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP2015000580 2015-03-16
EP2015002244 2015-11-09
PCT/EP2016/000473 WO2016146262A1 (en) 2015-03-16 2016-03-16 A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for treatment of colorectal cancer
EP16711529.4A EP3270955B1 (en) 2015-03-16 2016-03-16 A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for treatment of colorectal cancer

Publications (1)

Publication Number Publication Date
HRP20200491T1 true HRP20200491T1 (hr) 2020-06-26

Family

ID=55066559

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200491TT HRP20200491T1 (hr) 2015-03-16 2016-03-16 Novi kompleks koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za liječenje kolorektalnog karcinoma

Country Status (24)

Country Link
US (7) US20180133327A1 (enExample)
EP (4) EP3270955B1 (enExample)
JP (5) JP6862369B2 (enExample)
KR (2) KR102212451B1 (enExample)
CN (1) CN107428845A (enExample)
AU (5) AU2016232657B9 (enExample)
CA (3) CA2973770A1 (enExample)
CL (1) CL2017002345A1 (enExample)
CY (1) CY1122953T1 (enExample)
DK (3) DK3270957T3 (enExample)
EA (1) EA038049B1 (enExample)
ES (3) ES2781454T3 (enExample)
HR (1) HRP20200491T1 (enExample)
HU (3) HUE066851T2 (enExample)
IL (2) IL253416B (enExample)
LT (1) LT3270955T (enExample)
MX (1) MX2017011796A (enExample)
NZ (1) NZ733762A (enExample)
PH (1) PH12017501287A1 (enExample)
PL (3) PL3270957T3 (enExample)
PT (2) PT3270957T (enExample)
RS (1) RS60089B1 (enExample)
SI (1) SI3270955T1 (enExample)
WO (5) WO2016146143A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
CA3010779A1 (en) 2016-03-16 2017-09-21 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
CN109153722A (zh) 2016-04-08 2019-01-04 X4 制药有限公司 用于治疗癌症的方法
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
EP3471726A4 (en) 2016-06-21 2019-10-09 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
KR102879364B1 (ko) * 2016-09-21 2025-11-04 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
US11478538B2 (en) * 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
AU2017339577B2 (en) 2016-10-07 2021-12-02 Enterome S.A. Immunogenic compounds for cancer therapy
CN110088136A (zh) * 2016-10-13 2019-08-02 达纳-法伯癌症研究所有限公司 使用基因表达签名预测黑素瘤中对于ctla4封锁的应答和耐药性的组合物和方法
KR101875055B1 (ko) * 2016-10-19 2018-07-06 연세대학교 원주산학협력단 융합 단백질 및 그의 용도
KR102007203B1 (ko) * 2016-10-20 2019-08-05 연세대학교 원주산학협력단 융합 단백질 및 그의 용도
WO2018078620A1 (en) * 2016-10-25 2018-05-03 Urogen Pharma Ltd. Immunomodulating treatments of body cavities
US11229668B2 (en) * 2017-02-07 2022-01-25 Nantcell, Inc. Maximizing T-cell memory and compositions and methods therefor
CA3057715A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
US11433128B2 (en) * 2017-04-07 2022-09-06 Tianxin Wang Cell surface anchoring antigen conjugates to treat cancer
US12121573B2 (en) 2019-07-14 2024-10-22 Tianxin Wang Methods and agents including STING agonist to treat tumor
WO2018197926A1 (en) * 2017-04-26 2018-11-01 Robert Penchovsky Methods for creating novel antibacterial agents using chimeric antisense oligonucleotides
CA3066778A1 (en) * 2017-06-21 2018-12-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2019134018A1 (en) * 2018-01-05 2019-07-11 Telethon Kids Institute Vaccine conjugates and uses thereof
CN111918668A (zh) * 2018-02-16 2020-11-10 王天欣 治疗肿瘤细胞和癌症的方法和药剂
DK3773689T5 (da) 2018-04-11 2024-08-19 Enterome S A Antigene peptider til forebyggelse og behandling af kræft
EP3789491B1 (en) * 2018-05-02 2025-04-16 Kansai Medical University Educational Corporation Peptide and use therefor
EP3566718A1 (en) 2018-05-07 2019-11-13 Universitätsmedizin der Johannes Gutenberg-Universität Mainz A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer
JP2021530218A (ja) 2018-07-11 2021-11-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. 血液脳関門を超える薬剤の送達のための方法および組成物
EP3829652A4 (en) * 2018-08-01 2022-05-11 University of Maryland, Baltimore MODULATION OF MTORC1 ACTIVITY AND AUTOPHAGY BY CIB2-RHEB INTERACTION
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US12466892B2 (en) 2018-11-08 2025-11-11 The Regents Of The University Of California Systems and methods for targeting cancer cells
NZ777032A (en) 2018-11-16 2024-07-26 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
WO2020130546A1 (ko) * 2018-12-19 2020-06-25 한국화학연구원 인간 씨엘케이2 단백질 유래 세포막 투과 도메인
KR102351041B1 (ko) * 2018-12-19 2022-01-13 한국화학연구원 인간 lrrc24 단백질 유래 세포막 투과 도메인
WO2020130547A1 (ko) * 2018-12-19 2020-06-25 한국화학연구원 인간 엘알알씨24 단백질 유래 세포막 투과 도메인
WO2020130548A1 (ko) * 2018-12-19 2020-06-25 한국화학연구원 인간 쥐피에이티씨에치4 단백질 유래 세포막 투과 도메인
AU2020207087A1 (en) * 2019-01-12 2021-08-12 The Methodist Hospital Self-assembled peptide nanoparticle and use thereof
CN109859795A (zh) * 2019-02-20 2019-06-07 成都分迪科技有限公司 泛素化降解目标蛋白质的数据库
US20220184087A1 (en) * 2019-03-28 2022-06-16 The Penn State Research Foundation Methods and compositions relating to treatment of cancer
US11339190B2 (en) 2020-04-21 2022-05-24 Rush University Medical Center Peptides for the treatment of covid-19
US11667678B2 (en) 2019-04-21 2023-06-06 Rush University Medical Center Peptides for the treatment of COVID-19
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
WO2020231882A2 (en) 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
EP3827840A1 (en) * 2019-11-29 2021-06-02 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Teipp peptide variant and uses thereof
KR20220127847A (ko) * 2020-01-10 2022-09-20 더 브리검 앤드 우먼즈 하스피털, 인크. 뇌암을 치료하기 위해 혈액-뇌 장벽을 통해 면역요법제를 전달하기 위한 방법 및 조성물
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
KR102484312B1 (ko) * 2020-05-14 2023-01-02 한국화학연구원 고효능 사스 코로나바이러스 2 항원 및 이를 포함하는 백신 조성물
US12146000B2 (en) 2020-05-19 2024-11-19 Boehringer Ingelheim International Gmbh Bispecific and tetravalent CD137 and FAP molecules for the treatment of cancer
JP7598660B2 (ja) * 2020-06-04 2024-12-12 ザ カトリック ユニバーシティ オブ コリア インダストリー－アカデミック コーオペレイション ファウンデーション フラジェリン由来のｔｌｒ５アゴニストを有効成分として含む抗がん剤組成物
AU2021294322A1 (en) * 2020-06-26 2023-02-02 National Breast Cancer Coalition Breast cancer vaccine
MX2023002884A (es) 2020-09-14 2023-03-31 Boehringer Ingelheim Int Vacuna heterologa de estimulo primario.
KR102556731B1 (ko) * 2020-09-29 2023-07-21 주식회사 젠센 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
WO2022079175A1 (en) * 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
TW202231283A (zh) * 2020-10-19 2022-08-16 美商G1治療公司 用於治療轉移性大腸直腸癌之經改良之基於氟尿嘧啶之多藥劑化學治療
CN113817677B (zh) * 2021-09-29 2023-08-18 四川大学 泛酸或其衍生物与α-D-葡萄糖-1,6-二磷酸或其衍生物在促进DC迁移中的用途
WO2023059687A1 (en) * 2021-10-06 2023-04-13 Whispergenics, Inc. Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of cancers
KR102514849B1 (ko) * 2021-10-28 2023-03-28 전남대학교산학협력단 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물
CR20240374A (es) 2022-03-16 2024-10-22 Boehringer Ingelheim Int Antígenos tumorales, compuestos que comprenden los antígenos tumorales kras, tpx2 o aurka y usos de los mismos
US20250268949A1 (en) * 2022-04-13 2025-08-28 The Regents Of The University Of California Immune cell inhibition by immune checkpoint engagers
FR3143031A1 (fr) * 2022-12-08 2024-06-14 Université Grenoble Alpes Nouveaux peptides et leur utilisation en tant que transporteurs pour l’internalisation de molécules d’intérêt dans des cellules cibles
WO2024197792A1 (en) * 2023-03-31 2024-10-03 Beijing University Of Chinese Medicine A complex comprising a cell penetrating peptide and a copi sorting inhibitor and uses thereof
CN119925590A (zh) * 2025-04-08 2025-05-06 北京华诺泰生物医药科技有限公司 一种mpl复合佐剂及其制备方法和应用

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2728904B1 (fr) 1995-01-04 1997-03-14 Pasteur Institut Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EP3553085A1 (en) 1998-12-23 2019-10-16 Pfizer Inc Human momoclonal antibodies to ctla-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
DK1212422T3 (da) 1999-08-24 2007-07-02 Medarex Inc Humane CTLA-4-antistoffer og anvendelserne deraf
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
KR20090085697A (ko) 2000-02-23 2009-08-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
US7229960B2 (en) 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
AUPR593101A0 (en) 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
GB0218821D0 (en) 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
EA021644B1 (ru) 2002-10-17 2015-08-31 Генмаб А/С Человеческое моноклональное антитело против cd20 и его применение
US20090311279A1 (en) * 2003-10-15 2009-12-17 National Institutes Of Health Colorectal Cancer Antigen
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
MX2007009219A (es) * 2005-02-04 2008-01-16 Survac Aps Vacuna de peptido de survivina.
ES2291071B1 (es) 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
WO2008083174A2 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
CN103911358B (zh) * 2007-07-27 2017-03-01 伊玛提克斯生物技术有限公司 神经元和脑肿瘤的新型免疫疗法
US20090123467A1 (en) 2007-07-31 2009-05-14 The Johns Hopkins University Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP2011519834A (ja) * 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
CN102123732A (zh) 2008-06-20 2011-07-13 杜克大学 用于引发免疫应答的组合物，方法及试剂盒
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR101040281B1 (ko) 2008-08-22 2011-06-10 가톨릭대학교 산학협력단 Ｔａｔ-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물
US8074880B2 (en) 2008-12-01 2011-12-13 Research In Motion Limited Method, system and mobile device employing enhanced fingerprint authentication
CA3120172A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2755790A1 (en) 2009-03-16 2010-09-23 Mcmaster University Vaccination methods
SG176220A1 (en) 2009-05-27 2011-12-29 Glaxosmithkline Biolog Sa Casb7439 constructs
EA201270228A1 (ru) 2009-07-31 2012-09-28 Медарекс, Инк. Полноценные человеческие антитела к btla
IN2012DN02753A (enExample) 2009-08-31 2015-09-18 Amplimmune Inc
EP2476440B1 (en) * 2009-09-11 2017-08-02 Proyecto de Biomedicina Cima, S.L. Therapeutic compositions for the treatment of hpv-induced diseases
EP2480568B1 (en) * 2009-09-23 2016-04-20 Université Paris Descartes Polypeptides and nucleic acids for treating erbb2-dependent cancers
HUE037159T2 (hu) 2009-11-24 2018-08-28 Medimmune Ltd Targetált kötõdõ ágensek B7-H1 ellen
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2563399B1 (fr) 2010-04-26 2014-06-11 Université Joseph Fourier Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
SG186706A1 (en) 2010-07-30 2013-02-28 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
DK2608799T3 (en) 2010-08-24 2019-03-18 Univ Pittsburgh Commonwealth Sys Higher Education INTERLEUKIN 13-RECEPTOR-ALPHA 2-PEPTIDE-BASED BRAIN CANCER VACCINES
CN103402539B (zh) * 2010-09-14 2016-02-24 科学与工业研究委员会 一种用于产生对抗病原体的持久免疫和保护的合成免疫原
WO2012048190A1 (en) * 2010-10-08 2012-04-12 Regents Of The University Of Minnesota Annexin ii compositions and methods
KR101760464B1 (ko) * 2010-10-13 2017-07-24 사회복지법인 삼성생명공익재단 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도
EA026524B1 (ru) 2011-01-10 2017-04-28 Общество С Ограниченной Ответственностью "Биолаб 612" Применение агониста toll-подобного рецептора для лечения рака
US9187534B2 (en) 2011-03-11 2015-11-17 Universite De Geneve Multi-epitopic vaccine
US8795678B2 (en) * 2011-05-13 2014-08-05 Academia Sinica TLR-2 agonists and methods of use thereof
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
US8819679B2 (en) 2011-07-28 2014-08-26 International Business Machines Corporation Methods and systems for on-boarding applications to a cloud
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
EP2773651B1 (en) 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
CN104168922A (zh) * 2011-11-16 2014-11-26 安姆根有限公司 治疗表皮生长因子缺失突变体viii相关疾病的方法
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013120073A1 (en) * 2012-02-09 2013-08-15 Av Therapeutics, Inc. Synthetic toll-like receptor-4 (tlr-4) agonist peptides
CN109806387B (zh) 2012-07-13 2022-03-04 S-目标疗法有限公司 免疫调节疫苗
JP6306593B2 (ja) * 2012-09-13 2018-04-04 ユニベルシテ ドゥ ジュネーブ 細胞透過性ペプチド
MX375442B (es) 2012-09-21 2025-03-06 Intensity Therapeutics Inc Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.
WO2014070663A1 (en) * 2012-10-29 2014-05-08 Anderson David E Compositions and methods for diagnosis and treatment of malignant gliomas
AU2014248711A1 (en) * 2013-03-13 2015-09-10 Neostem Oncology, Llc Individualized high purity colon carcinoma stem cells, methods and use of the same
US20160257961A1 (en) * 2013-11-06 2016-09-08 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
WO2015073632A1 (en) * 2013-11-13 2015-05-21 Regents Of The University Of Minnesota Annexin ii variant compositions and methods
RU2707530C2 (ru) * 2014-01-02 2019-11-27 Мемориал Слоан Кеттеринг Кэнсер Сентер Детерминанты ответа раковой опухоли на иммунотерапию
CA2950960A1 (en) * 2014-06-06 2015-12-10 Solstice Biologics, Ltd. Polynucleotide constructs having bioreversible and non-bioreversible groups
EP3212772A4 (en) 2014-10-31 2018-10-03 Massachusetts Institute of Technology Delivery of biomolecules to immune cells
KR20170080697A (ko) 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
BR102015025502B1 (pt) 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição
JPWO2017002345A1 (ja) 2015-06-29 2018-04-19 パナソニックＩｐマネジメント株式会社 冷蔵庫
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
MX2018008413A (es) 2016-01-08 2019-02-20 Replimune Ltd Virus oncolitico modificado.
AU2017207532A1 (en) 2016-01-11 2018-08-16 Turnstone Limited Partnership Oncolytic virus and checkpoint inhibitor combination therapy
CA3010779A1 (en) 2016-03-16 2017-09-21 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
KR20190038480A (ko) 2016-05-09 2019-04-08 턴스톤 리미티드 파트너쉽 프라임:부스트 병용 요법제
PL417980A1 (pl) 2016-07-16 2018-01-29 Univ Warszawski Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu
WO2018053508A1 (en) 2016-09-19 2018-03-22 The University Of North Carolina At Chapel Hill Methods and compositions for inducing an immune response
KR102879364B1 (ko) 2016-09-21 2025-11-04 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
US12303561B2 (en) 2017-04-03 2025-05-20 Biontech Us Inc. Protein antigens and uses thereof
RU2020128830A (ru) 2018-02-02 2022-03-03 Новартис Аг Комбинация агониста sting и il-15/il-15rа для лечения рака
CA3110102A1 (en) 2018-06-20 2019-12-26 Yale University Rig-i agonists and treatments using same
WO2020010451A1 (en) 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
MX2023002884A (es) 2020-09-14 2023-03-31 Boehringer Ingelheim Int Vacuna heterologa de estimulo primario.
WO2022079175A1 (en) 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist

Also Published As

Publication number Publication date
IL253416B (en) 2021-08-31
PH12017501287A1 (en) 2018-02-05
WO2016146262A1 (en) 2016-09-22
WO2016146259A1 (en) 2016-09-22
NZ733762A (en) 2023-09-29
PT3270955T (pt) 2020-04-09
LT3270955T (lt) 2020-05-11
JP6882207B2 (ja) 2021-06-02
AU2021282506A1 (en) 2022-01-06
IL285273A (en) 2021-09-30
JP6862369B2 (ja) 2021-04-21
JP7190528B2 (ja) 2022-12-15
EP3270957A1 (en) 2018-01-24
ES2781455T3 (es) 2020-09-02
EP3693009B1 (en) 2024-02-21
US20220175933A1 (en) 2022-06-09
JP2021119182A (ja) 2021-08-12
MX2017011796A (es) 2018-04-11
WO2016146260A1 (en) 2016-09-22
US12220450B2 (en) 2025-02-11
KR20170128516A (ko) 2017-11-22
PT3270957T (pt) 2020-04-21
IL253416A0 (en) 2017-09-28
JP2018509936A (ja) 2018-04-12
EA201792045A1 (ru) 2018-03-30
ES2978792T3 (es) 2024-09-20
AU2016232656A1 (en) 2017-08-10
JP2018510215A (ja) 2018-04-12
PL3270957T3 (pl) 2020-07-27
US20180133338A1 (en) 2018-05-17
US20180133327A1 (en) 2018-05-17
HUE066851T2 (hu) 2024-09-28
US20220031850A1 (en) 2022-02-03
JP2021104038A (ja) 2021-07-26
EA038049B1 (ru) 2021-06-29
JP2018509935A (ja) 2018-04-12
CN107428845A (zh) 2017-12-01
HUE048808T2 (hu) 2020-08-28
EP3270957B1 (en) 2020-01-08
JP7179896B2 (ja) 2022-11-29
PL3693009T3 (pl) 2024-06-10
DK3270955T3 (da) 2020-03-16
JP6993240B2 (ja) 2022-02-15
WO2016146261A1 (en) 2016-09-22
US20220040314A1 (en) 2022-02-10
SI3270955T1 (sl) 2020-08-31
EP3693009A1 (en) 2020-08-12
RS60089B1 (sr) 2020-05-29
DK3270957T3 (da) 2020-03-30
US12178788B2 (en) 2024-12-31
AU2016232659A1 (en) 2017-08-10
KR102212451B1 (ko) 2021-02-04
AU2016232657B2 (en) 2021-07-29
ES2781454T3 (es) 2020-09-02
AU2016232659B2 (en) 2021-07-01
HUE048807T2 (hu) 2020-08-28
CL2017002345A1 (es) 2018-05-18
CY1122953T1 (el) 2021-10-29
US20180133295A1 (en) 2018-05-17
IL285273B (en) 2022-06-01
AU2021282506B2 (en) 2023-02-16
US12453762B2 (en) 2025-10-28
KR102386172B1 (ko) 2022-04-12
PL3270955T3 (pl) 2020-07-27
AU2016232657B9 (en) 2021-12-02
EP3270955A1 (en) 2018-01-24
CA2973747A1 (en) 2016-09-22
KR20210013670A (ko) 2021-02-04
CA2973770A1 (en) 2016-09-22
BR112017015906A2 (pt) 2018-04-10
AU2021218097A1 (en) 2021-09-09
AU2021218097B2 (en) 2023-01-19
EP3270954A1 (en) 2018-01-24
AU2016232657A1 (en) 2017-08-10
EP3270955B1 (en) 2020-01-08
WO2016146143A1 (en) 2016-09-22
DK3693009T3 (da) 2024-04-29
US20180133339A1 (en) 2018-05-17
CA2973757A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
HRP20200491T1 (hr) Novi kompleks koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za liječenje kolorektalnog karcinoma
JP2018509936A5 (enExample)
AR121588A2 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
JP2018510215A5 (enExample)
CL2020000987A1 (es) Nuevo péptido de seq id no: 89 para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer (divisional de la solicitud no. 201701819)
PE20240645A1 (es) Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
MX2018011223A (es) Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer.
JP2019528693A5 (enExample)
CR20180491A (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón amicrocítico y otros tipos de cáncer
EA202191027A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
EA201992664A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
CO2018012914A2 (es) Péptidos y combinación de péptidos como dianas y para inmunoterapia contra el cáncer de vesícula biliar y el colangiocarcinoma, así como otros tipos de cáncer
MY198110A (en) Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
MX2021003067A (es) Peptidos restringidos por b*44 para el uso en la inmunoterapia contra el cancer y metodos relacionados.
CL2020002950A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer (divisional de la solicitud 201902878)
CL2021001525A1 (es) Nuevos péptidos y nueva combinación de péptidos como dianas y para el uso en la inmunoterapia contra el cáncer de vesícula biliar y el colangiocarcinoma, así como otros tipos de cáncer (divisional de la solicitud no. 201803293)
AR122383A2 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
NZ746513A (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
AR107897A1 (es) Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer
EA202191120A3 (ru) Пептиды и их комбинации для применения в иммунотерапии раковых заболеваний
EA202190465A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака
AR105011A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia y métodos para crear soportes para el uso contra el cáncer de páncreas y otros tipos de cáncer
EA202092502A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов рака
MY199372A (en) Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
CR20200477A (es) PÉPTIDOS Y COMBINACIÒN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Divisional 2017-0522)